CTOs on the Move

Hillcrest Educational Centers

www.hillcrestec.org

 
Hillcrest Educational Foundation is a private not-for-profit agency that provides a range of individualized and comprehensive clinical, psychological and special education services for children, adolescents and families in Berkshire County, MA and the Northeast. The students served by Hillcrest in nonresidential and residential programs have complex psychiatric, behavioral and/or developmental disorders, including Autism Spectrum Disorders, and a variety of high-risk behaviors. The programs and services provided by the Hillcrest Educational Foundation are state licensed and certified, and Hillcrest Educational Centers, including Hillcrest Community Support Services, is accredited in behavioral health care by the Joint Commission.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Keystone Peer Review Organization

Keystone Peer Review Organization is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.

EmpiRx Health

EmpiRx Health is challenging the status quo in today`s pharmacy benefit management industry by offering evidence-based clinical care programs that are aligned with our member`s needs. Our concierge model along with our proactive oversight and agile technology platform provide actionable insight to protect our clients and their members from ever-rising drug costs.

Capital Home Health Care

Capital Home Health Care is a Leesburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kerby Centre

Kerby Centre is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.